Abcellera Biologics Inc
$ 3.10
5.44%
13 Feb - close price
- Market Cap 880,045,000 USD
- Current Price $ 3.10
- High / Low $ 3.22 / 3.05
- Stock P/E N/A
- Book Value 3.22
- EPS -0.57
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -0.17 %
- 52 Week High 6.51
- 52 Week Low 1.89
About
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$9.83
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-05 | 2025-02-18 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-21 |
| Reported EPS | -0.19 | -0.12 | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 | -0.17 | -0.1 | -0.11 | -0.14 | -0.1 |
| Estimated EPS | -0.14 | -0.14 | -0.17 | -0.1471 | -0.15 | -0.14 | -0.17 | -0.13 | -0.13 | -0.13 | -0.14 | -0.01 |
| Surprise | -0.05 | 0.02 | 0.02 | 0.0271 | -0.02 | 0.01 | 0.03 | -0.04 | 0.03 | 0.02 | 0 | -0.09 |
| Surprise Percentage | -35.7143% | 14.2857% | 11.7647% | 18.4228% | -13.3333% | 7.1429% | 17.6471% | -30.7692% | 23.0769% | 15.3846% | 0% | -900% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.16 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABCL
2026-02-12 11:42:04
The State of Michigan Retirement System significantly increased its stake in AbCellera Biologics Inc. (NASDAQ:ABCL) by 712.6% in the third quarter, acquiring an additional 350,775 shares to hold a total of 400,000 shares valued at approximately $2.01 million. Despite this increased institutional ownership, AbCellera's shares opened at $3.13, trade below their 200-day average, and have a negative P/E ratio. Analyst sentiment is mixed, with downgrades from several firms leading to a consensus "Hold" rating and a target price of $7.75.
2026-02-11 22:27:49
AbCellera (Nasdaq: ABCL) announced its participation in three upcoming investor conferences in March and April 2026: the TD Cowen 46th Annual Health Care Conference, KeyBanc Capital Markets Healthcare Forum, and Bloom Burton & Co. Healthcare Investor Conference. Webcasts of these presentations, along with replays, will be available on the company's Investor Relations website. AbCellera is a clinical-stage biotechnology company focused on developing antibody-based medicines.
2026-02-11 21:28:04
AbCellera (Nasdaq: ABCL) announced its participation in three upcoming investor conferences in March and April 2026: the TD Cowen 46th Annual Health Care Conference, the KeyBanc Capital Markets Healthcare Forum, and the Bloom Burton & Co. Healthcare Investor Conference. Live audio webcasts of the presentations will be available on AbCellera's Investor Relations website, with replays accessible afterward. AbCellera is a clinical-stage biotechnology company focused on antibody-based medicine discovery and development.
2026-02-06 10:30:00
AbCellera Biologics is shifting its focus from being a service-oriented antibody discovery platform to a clinical-stage biotech, with proprietary candidates ABCL635 and ABCL575 progressing in Phase 1 trials. This strategic change, alongside a portfolio of royalty streams from partnered programs, indicates a move towards owning drug assets. The company's investment narrative is now heavily reliant on clinical catalysts and data readouts through 2026, posing risks due to its current loss-making status and an expensive valuation tied to unproven clinical and royalty optionality.
2026-02-05 20:58:57
AbCellera Biologics (ABCL) is shifting its focus from being a service-oriented antibody discovery platform to a clinical-stage biotech. The company now has proprietary drug candidates, ABCL635 and ABCL575, in Phase 1 trials, and over 100 partnered programs that could generate royalties. This strategic change aims to create new value by owning drug assets, moving its investment narrative from service revenue to clinical catalysts, with upcoming data readouts being crucial for its short-term performance.
2026-01-31 01:33:59
AbCellera Biologics (NasdaqGS:ABCL) has started dosing patients in the Phase 2 portion of its clinical trial for ABCL635, a non-hormonal treatment for menopause-related vasomotor symptoms. This advancement is significant for the company's pipeline as its shares are currently trading well below analyst targets and Simply Wall St's fair value estimate. Investors are advised to monitor future trial updates and potential partnerships, keeping in mind the inherent risks of clinical development.
